NDAORALTABLET
Approved
Jul 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALURON (hydroflumethiazide) is a thiazide diuretic oral tablet approved in 1959 for hypertension and edema management. It works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion to reduce blood volume and blood pressure. This is a legacy small-molecule antihypertensive with a well-established safety and efficacy profile spanning decades of clinical use.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), this product likely has a small, maintenance-focused team focused on generic transition management and loss-of-exclusivity mitigation rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
Started Mar 2013
0Hypertension
Career Relevance
Working on SALURON offers limited upside career trajectory; roles are primarily defensive, cost-management, and compliance-focused rather than growth-oriented. This product is best suited for professionals seeking stable, maintenance-phase responsibilities or portfolio transition experience rather than career acceleration.
Brand Manager (Legacy Products)
Worked on SALURON at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.